Norepinephrine and Concentric Hypertrophy in Patients With End-Stage Renal Disease
-
- Carmine Zoccali
- From the CNR, Centre of Clinical Physiology and Division of Nephrology (C.Z., F.M., G.T., S.P., S.C.), Reggio Calabria, Italy; Cardiology Unit, Morelli Hospital (F.A.B.), Reggio Calabria, Italy; and Institute of Internal Medicine and Nephrology “L. Condorelli,” Catania University (A.C., L.S.M.), Italy.
-
- Francesca Mallamaci
- From the CNR, Centre of Clinical Physiology and Division of Nephrology (C.Z., F.M., G.T., S.P., S.C.), Reggio Calabria, Italy; Cardiology Unit, Morelli Hospital (F.A.B.), Reggio Calabria, Italy; and Institute of Internal Medicine and Nephrology “L. Condorelli,” Catania University (A.C., L.S.M.), Italy.
-
- Giovanni Tripepi
- From the CNR, Centre of Clinical Physiology and Division of Nephrology (C.Z., F.M., G.T., S.P., S.C.), Reggio Calabria, Italy; Cardiology Unit, Morelli Hospital (F.A.B.), Reggio Calabria, Italy; and Institute of Internal Medicine and Nephrology “L. Condorelli,” Catania University (A.C., L.S.M.), Italy.
-
- Saverio Parlongo
- From the CNR, Centre of Clinical Physiology and Division of Nephrology (C.Z., F.M., G.T., S.P., S.C.), Reggio Calabria, Italy; Cardiology Unit, Morelli Hospital (F.A.B.), Reggio Calabria, Italy; and Institute of Internal Medicine and Nephrology “L. Condorelli,” Catania University (A.C., L.S.M.), Italy.
-
- Sebastiano Cutrupi
- From the CNR, Centre of Clinical Physiology and Division of Nephrology (C.Z., F.M., G.T., S.P., S.C.), Reggio Calabria, Italy; Cardiology Unit, Morelli Hospital (F.A.B.), Reggio Calabria, Italy; and Institute of Internal Medicine and Nephrology “L. Condorelli,” Catania University (A.C., L.S.M.), Italy.
-
- Francesco Antonio Benedetto
- From the CNR, Centre of Clinical Physiology and Division of Nephrology (C.Z., F.M., G.T., S.P., S.C.), Reggio Calabria, Italy; Cardiology Unit, Morelli Hospital (F.A.B.), Reggio Calabria, Italy; and Institute of Internal Medicine and Nephrology “L. Condorelli,” Catania University (A.C., L.S.M.), Italy.
-
- Alessandro Cataliotti
- From the CNR, Centre of Clinical Physiology and Division of Nephrology (C.Z., F.M., G.T., S.P., S.C.), Reggio Calabria, Italy; Cardiology Unit, Morelli Hospital (F.A.B.), Reggio Calabria, Italy; and Institute of Internal Medicine and Nephrology “L. Condorelli,” Catania University (A.C., L.S.M.), Italy.
-
- Lorenzo Salvatore Malatino
- From the CNR, Centre of Clinical Physiology and Division of Nephrology (C.Z., F.M., G.T., S.P., S.C.), Reggio Calabria, Italy; Cardiology Unit, Morelli Hospital (F.A.B.), Reggio Calabria, Italy; and Institute of Internal Medicine and Nephrology “L. Condorelli,” Catania University (A.C., L.S.M.), Italy.
Abstract
<jats:p> We have recently observed that in patients with end-stage renal disease (ESRD) raised plasma norepinephrine (NE) is an independent predictor of incident cardiovascular events but that its prognostic power is reduced when this sympathetic marker is tested in statistical models including also left ventricular mass. Because left ventricular hypertrophy (LVH) may be a mechanism whereby NE contributes to the high rate of cardiovascular events in ESRD, we examined the relationship between plasma NE and echocardiographic parameters of left ventricle mass in a large group of ESRD patients. Mean wall thickness (MWT) was higher in patients in the third NE tertile than in the other 2 tertiles ( <jats:italic>P</jats:italic> =0.001), and such an increase was paralleled by a rise in relative wall thickness (RWT) ( <jats:italic>P</jats:italic> =0.006). Concentric LVH was more prevalent in patients in the third NE tertile (46%) than in the second (38%) and first (25%) NE tertiles. Multivariate regression analysis confirmed that the association of plasma NE with the muscular component of left ventricle (MWT) and with RWT was independent ( <jats:italic>P</jats:italic> ≤0.001) of other cardiovascular risk factors, and in these models, plasma NE ranked as the second correlate of MWT and RWT. Similarly, multiple logistic regression analysis showed that the association of plasma NE with concentric LVH was strong and again independent of other risk factors ( <jats:italic>P</jats:italic> =0.003). Plasma NE is associated to concentric LVH in ESRD patients. These observations constitute a sound basis for testing the effect of anti-adrenergic drugs on left ventricle mass and on cardiovascular outcomes in patients with ESRD. </jats:p>
Journal
-
- Hypertension
-
Hypertension 40 (1), 41-46, 2002-07
Ovid Technologies (Wolters Kluwer Health)
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1362262946337142784
-
- NII Article ID
- 30022676939
-
- ISSN
- 15244563
- 0194911X
-
- Data Source
-
- Crossref
- CiNii Articles